Clinical trials have historically hewn to a rigid format. A trial is designed, conducted according to that design, and then results are analyzed. Making changes in the midst of the study was a no-no.
An investigational antiviral drug Gilead Sciences has been developing to treat infections caused by the Ebola virus will be tested in about 1,000 adults diagnosed with COVID-19, the novel coronavirus that has infected tens of thousands of people and killed more... Read more »
Genentech is the latest company to enter a drug discovery partnership with Bicycle Therapeutics, adding a new alliance in cancer research for the clinical-stage biotech.
As Esperion Therapeutics steered its cholesterol-lowering drug through clinical testing and regulatory review, CEO Tim Mayleben did something unusual for a pharmaceutical executive: he spoke openly about price. Specifically, he talked about how inexpensive the drug would be.
As early as... Read more »
In what looks to be a transformative year for potential treatments of nonalcoholic steatohepatitis, the liver disease better known as NASH, another biotech has revealed that its experimental drug appears to improve the condition compared to a placebo.
NGM Biopharmaceuticals (NASDAQ:... Read more »
Spruce Biosciences has raised $88 million to advance clinical testing of a drug for a rare inherited endocrine disorder that can lead to a potentially life-threatening hormonal imbalance.
A Teva Pharmaceutical drug in testing as a treatment for tics in pediatric patients with moderate-to-severe Tourette syndrome has failed two late-stage trials.
Join Xconomy on April 29 at Takeda Pharmaceuticals’ Boston location for the next in our Xcelerating Life Sciences event series: Biopharma’s Future in Digital Health. The half-day conference will bring together innovators, executives, rising pioneers, entrepreneurs, investors, and scientists to... Read more »
Three months after resTORbio’s lead drug failed a pivotal test treating lung infections in the elderly, the company is now looking for someone to buy the firm or strike a deal for its technology.
CNS and cancer will be biopharma battlegrounds this year according to Philadelphia-based Clarivate Analytics, which says new medicines will reshape the US market.
The US Food and Drug Administration (FDA) looks set to approve several innovative therapies for central nervous system... Read more »